Edwards Lifesciences (EW) Gross Profit (2009 - 2026)

Edwards Lifesciences has reported Gross Profit for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 15.74% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $4.9 billion (up 11.8% YoY), and the FY2025 full-year result was $4.7 billion, up 9.52% from the prior year.
• Gross Profit for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Gross Profit was $1.3 billion in Q1 2026, with the low at $528.7 million in Q4 2022.
• Average Gross Profit over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Gross Profit slumped 48.18% in 2022 and surged 92.06% in 2023.
• Tracing EW's Gross Profit over 5 years: stood at $528.7 million in 2022, then soared by 92.06% to $1.0 billion in 2023, then rose by 7.7% to $1.1 billion in 2024, then grew by 12.16% to $1.2 billion in 2025, then increased by 4.84% to $1.3 billion in 2026.
• The last three Gross Profit figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison